MECP2 and breast carcinoma: From the above, we can speculate that MECP2 can decrease the expression of mTOR to reduce angiogenesis, but miR‐194 downregulates the expression of MECP2 to promote angiogenesis, thus increasing the sensitivity of breast cancer cells to rapamycin treatment.